Global biotechnology company Nona Biosciences announced on Friday that its partner Pfizer Inc (NYSE:PFE) will present an abstract detailing the first-in-human Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

MesoC2 is a first-in-class mesothelin (MSLN)-targeting antibody-drug conjugate (ADC) originally developed using Nona's proprietary Harbour Mice and integrated ADC platforms, which was licensed to Pfizer in 2023 under a global rights agreement.

Pfizer is currently evaluating the ADC in a Phase 1, open-label study in patients with advanced solid tumours, including mesothelioma, platinum-resistant ovarian cancer (PROC), pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), endometrial cancer (EC), and colorectal cancer (CRC).